Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8478633 | Molecular and Cellular Neuroscience | 2014 | 9 Pages |
Abstract
Systemic administration of human umbilical cord blood (HUCB) mononuclear cells (MNC) following middle cerebral artery occlusion (MCAO) in the rat reduces infarct size and, more importantly, restores motor function. The HUCB cell preparation is composed of immature T-cells, B-cells, monocytes and stem cells. In this study we examined whether the beneficial effects of HUCB injection were attributable to one of these cell types. Male Sprague Dawley rats underwent permanent MCAO followed 48Â h later by intravenous administration of HUCB MNC preparations depleted of either CD14Â + monocytes, CD133Â + stem cells, CD2Â + T-cells or CD19Â + B cells. Motor function was measured prior to MCAO and 30Â days post-stroke. When CD14Â + monocytes were depleted from the HUCB MNC, activity and motor asymmetry were similar to the MCAO only treated animals. Monocyte depletion prevented HUCB cell treatment from reducing infarct size while monocyte enrichment was sufficient to reduce infarct size. Administration of monocyte-depleted HUCB cells did not suppress Iba1 labeling of microglia in the infarcted area relative to treatment with the whole HUCB preparation. These data demonstrate that the HUCB monocytes provide the majority of the efficacy in reducing infarct volume and promoting functional recovery.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cell Biology
Authors
T.A. Womble, S. Green, M. Shahaduzzaman, J. Grieco, P.R. Sanberg, K.R. Pennypacker, A.E. Willing,